CUDC-907 decreased HDACs and PI3K signaling in a panel of eight prostate cancer cell lines, promoted apoptosis in a dose-dependent manner linked with enhanced pro-apoptotic Bim, and lowered antiapoptotic Mcl-1 and Bcl-xL expression in 22Rv1 CRPC cells, and inhibited HDACs and PI3K signaling. Here, PIK3CA is linked to prostate carcinoma.